Context Therapeutics (CNTX) Institutional Ownership $1.63 -0.02 (-1.21%) (As of 11/20/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Context Therapeutics (NASDAQ:CNTX)CurrentInstitutional OwnershipPercentage14.03%Number ofInstitutional Buyers(last 12 months)10TotalInstitutional Inflows(last 12 months)$40.01MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$1.28M Get CNTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Context Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CNTX Institutional Buying and Selling by Quarter Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Context Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/16/2024 Geode Capital Management LLC575,899$1.13M0.0%-6.8%0.768% 11/15/2024 Y Intercept Hong Kong Ltd45,635$89K0.0%N/A0.061% 11/15/2024 State Street Corp111,907$219K0.0%+21.5%0.149% 11/14/2024 Ally Bridge Group NY LLC1,757,524$3.45M1.8%-6.8%2.343% 11/13/2024 Great Point Partners LLC6,934,982$13.59M4.0%-6.5%9.247% 8/20/2024 Nantahala Capital Management LLC1,935,484$3.88M0.2%N/A2.581% Get the Latest News and Ratings for CNTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/16/2024 Driehaus Capital Management LLC2,258,065$4.53M0.0%N/A3.011% 8/15/2024 Blue Owl Capital Holdings LP5,161,290$10.35M2.9%N/A6.882% 8/15/2024 Affinity Asset Advisors LLC1,619,140$3.25M0.4%+392.4%2.159% 8/14/2024 Great Point Partners LLC7,419,355$14.88M2.8%N/A9.893% 8/14/2024 Ally Bridge Group NY LLC1,886,232$3.78M2.3%+159.8%2.515% 8/9/2024 Renaissance Technologies LLC65,200$131K0.0%+63.4%0.087% 5/29/2024 Opaleye Management Inc.1,108,357$1.53M0.3%+13.7%1.478% 2/15/2024 Opaleye Management Inc.975,000$1.10M0.3%N/A6.107% 11/15/2023 Affinity Asset Advisors LLC328,817$497K0.1%+22.9%2.059% 8/21/2023 Affinity Asset Advisors LLC267,574$428K0.1%N/A1.675% 7/21/2023 Clear Harbor Asset Management LLC36,000$58K0.0%N/A0.225% 2/16/2023 AIGH Capital Management LLC1,143,745$745K0.2%-11.5%7.162% 2/14/2023swisspartners Ltd.180,000$119K0.2%+111.8%1.127% 11/14/2022 Worth Venture Partners LLC322,628$358K0.2%+8.4%2.021% 11/1/2022swisspartners Ltd.85,000$94K0.1%+101.3%0.532% 8/13/2022Virtu Financial LLC46,445$98K0.0%N/A0.291% 8/12/2022 Affinity Asset Advisors LLC883,654$1.87M0.8%+13.6%5.535% 5/4/2022swisspartners Ltd.14,315$4.98M3.5%-66.1%0.090% 2/14/2022 Altium Capital Management LP493,531$1.31M0.4%N/A4.501% 2/11/2022 QCM Cayman Ltd.14,041$37K0.2%N/A0.128% 2/10/2022 AIGH Capital Management LLC762,721$2.03M0.6%N/A6.955% 2/9/2022swisspartners Ltd.42,235$114K0.1%N/A0.385% (Data available from 1/1/2016 forward) CNTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CNTX shares? During the previous two years, 14 institutional investors and hedge funds held shares of Context Therapeutics. The most heavily invested institutionals were Great Point Partners LLC ($13.59M), Blue Owl Capital Holdings LP ($10.35M), Driehaus Capital Management LLC ($4.53M), Nantahala Capital Management LLC ($3.88M), Ally Bridge Group NY LLC ($3.45M), Affinity Asset Advisors LLC ($3.25M), and Opaleye Management Inc. ($1.53M).Learn more on CNTX's institutional investors. What percentage of Context Therapeutics stock is owned by institutional investors? 14.03% of Context Therapeutics stock is owned by institutional investors. Learn more on CNTX's institutional investor holdings. Which institutional investors have been buying Context Therapeutics stock? Of the 12 institutional investors that purchased Context Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Great Point Partners LLC ($7.42M), Blue Owl Capital Holdings LP ($5.16M), Driehaus Capital Management LLC ($2.26M), Nantahala Capital Management LLC ($1.94M), Affinity Asset Advisors LLC ($1.62M), Ally Bridge Group NY LLC ($1.16M), and Opaleye Management Inc. ($1.11M). How much institutional buying is happening at Context Therapeutics? Institutional investors have bought a total of 20,883,707 shares in the last 24 months. This purchase volume represents approximately $40.65M in transactions. Which Context Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Context Therapeutics stock in the last 24 months: Great Point Partners LLC ($484.37K), AIGH Capital Management LLC ($148.03K), Ally Bridge Group NY LLC ($128.71K), and Geode Capital Management LLC ($42.28K). How much institutional selling is happening at Context Therapeutics? Institutional investors have sold a total of 803,382 shares in the last 24 months. This volume of shares sold represents approximately $1.38M in transactions. Related Companies UNCY Major Shareholders MREO Major Shareholders ARCT Major Shareholders ALMS Major Shareholders YMAB Major Shareholders ZVRA Major Shareholders ESPR Major Shareholders RGNX Major Shareholders SLRN Major Shareholders MGTX Major Shareholders This page (NASDAQ:CNTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
